Objectives: The purpose of the current study was to investigate whether taking valproic acid (VPA) was protective against coronavirus disease 2019 (COVID-19) infection or severity in patients with epilepsy.
Methods: This was a questionnaire study of 150 people who were taking VPA in monotherapy or polytherapy (since the start of the pandemic or longer) and also 150 people who were not taking VPA (since the start of the pandemic), registered in our epilepsy database. The data compared rates of the seropositivity and severity of infection of COVID-19 between the 2 groups. The latter was assessed, by proxy, vis-à-vis rates of hospital admission and intensive care unit admission.
Results: Two hundred forty-one patients were studied, including 130 (53.9%) male and 111 (46.1%) female patients. The mean age of the patients was 30.7 ± 11.4 years. The infection rate and severity of COVID-19 did not significantly differ among patients who were taking VPA and those who were not taking VPA (P = 0.587) and (P = 0.648), respectively.
Conclusions: In this pilot study, no support was found for the hypothesis of a protective effect of VPA against the infectivity rate of COVID-19. Neither was there any indication of a disease-modulating effect of VPA in people with active COVID-19 infection. Larger, randomized controlled trials would be warranted to substantiate our conclusion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0000000000000529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction Trough Concentrations of Valproic Acid Among Chinese Adult Patients with Epilepsy Using Machine Learning Techniques.
Pharm Res
January 2025
Department of Pharmacy, Jinshan Hospital Affiliated to Fudan University, Shanghai, China.
Objective: This study aimed to establish an optimal model based on machine learning (ML) to predict Valproic acid (VPA) trough concentrations in Chinese adult epilepsy patients.
Methods: A single-center retrospective study was carried out at the Jinshan Hospital affiliated with Fudan University from January 2022 to December 2023. A total of 102 VPA trough concentrations were split into a derivation cohort and a validation cohort at a ratio of 8:2.
Which is the most cost-effective antiseizure medication for initial monotherapy for focal epilepsy?
Epilepsia
January 2025
Department of Pharmacy, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Objective: An increasing number of antiseizure medications (ASMs) are approved for monotherapy for focal epilepsy, but direct comparisons of the lifetime cost-effectiveness of all existing treatment strategies are lacking. This study aims to compare the cost-effectiveness of new ASMs and traditional ASMs as first-line monotherapy for newly diagnosed focal epilepsy.
Method: We used a Markov model to evaluate the lifetime cost-effectiveness of 10 ASMs in the treatment of focal epilepsy, with lacosamide (LCM) as a control, from the perspective of society in the United States.
Aim: This study was conducted to evaluate the in vitro effects of hydroxychloroquine (HCQ) on histone deacetylase (HDAC) enzyme activity and interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha (TNF-α) expression. HDAC enzyme activity and the expression of inflammation markers were tested, with the presence of the HDAC inhibitor valproic acid, in human primary cell cultures prepared from two different tissues.
Material And Methods: Primary cell cultures were prepared.
Vagus nerve stimulation rescues impaired fear extinction and social interaction in a rat model of autism spectrum disorder.
J Affect Disord
January 2025
Department of Neuroscience, School of Behavioral and Brain Sciences, The University of Texas at Dallas, 800 W Campbell Rd., Richardson, TX 75080, USA; Texas Biomedical Device Center (TxBDC), The University of Texas at Dallas, 800 W Campbell Rd., Richardson, TX 75080, USA. Electronic address:
Clinical diagnosis of anxiety disorders is highly prevalent in autism spectrum disorders (ASD). Available treatments for anxiety offer limited efficacy in the ASD population. Vagus nerve stimulation (VNS) has an anxiolytic effect in rats and, when coupled with fear extinction training, VNS enhances extinction of fear in healthy rats.
View Article and Find Full Text PDFEffect of Valproate Coprescription on Clozapine Pharmacokinetics in Clinical Practice.
J Clin Psychopharmacol
January 2025
Department of Psychological Medicine, University of Otago, Wellington, New Zealand.
Background: Sodium valproate has been coprescribed with clozapine for seizure prophylaxis and for augmentation in treatment-refractory schizophrenia. However, the effect of valproate on clozapine metabolism and on the incidence of clozapine-related side effects is unclear.
Methods: We compared clozapine dose and plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in smokers and nonsmokers of both sexes in samples submitted for clozapine therapeutic drug monitoring, 1996-2017 in relation to valproate coprescription.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!